

PHA 4301 (3167/12Z) PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of John P. McKearn et al. Art Unit 1614 Serial No. 09/843,132 Filed April 25, 2001 Confirmation No. 8349

ANTIANGIOGENIC COMINATION THERAPY FOR THE TREATMENT OF

August 14, 2003

RECEIVED

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VIRGINIA 22313-1450

CANCER

AUG 1 9 2003

TECH CENTER 1600/2900

SIR:

## INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, Applicants submit copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

Please note that Applicants make no representation as to the accuracy or completeness of the translations of the abstracts submitted herewith.

In preparation of this Information Disclosure Statement, Applicants determined that approximately 583 references were cited in the application. In an effort to reduce the burden on the Office, each reference was briefly reviewed by an attorney. This review eliminated any reference that was determined to be irrelevant or merely cumulative. If the Office would like a copy of the eliminated references, they can be provided at the Office's request.

A check in the amount of \$180.00 is enclosed to cover the fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345.

Also enclosed is Applicants' executed Power of Attorney.

Respectfully submitted

Kathryn J. Doty, Reg. No. 40,593 SENNIGER, POWERS, LEAVITT & ROEDEL One Metropolitan Square, 16th Floor St. Louis, Missouri 63102

(314) 231-5400

KJD/msc
\*Enclosures

Express Mail Label No. EV 327052305 US - 1 Box

## FEE TRANSMITTAL

Application Number 09/843,132 Filing Date April 25, 2001 Confirmation No. 8349 Inventor(s) John P. McKearn et al. Attorney Docket Number PHA 4301(3167/12Z)

## METHOD OF PAYMENT

170		
' أِ وَ	•	FEE TRANSMITTAL
⟨Filir	ng Dat	on Number 09/843,132  te April 25, 2001 ion No. 8349 s) John P. McKearn et al. Docket Number PHA 4301(3167/12Z)  METHOD OF PAYMENT  The Commissioner is hereby authorized to charge the indicated fees to Deposit Account No. 19-1345.  The Commissioner is hereby authorized to charge any
Inver	ntor(s	s) John P. McKearn et al. Docket Number PHA 4301(3167/12Z)
		METHOD OF PAYMENT
1.	[ ]	The Commissioner is hereby authorized to charge the indicated fees to Deposit Account No. 19-1345.
	[ ]	The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 to Deposit Account No. 19-1345.
	[ ]	Applicant claims small entity status.
2.	[X]	Check Enclosed. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345.
		FEE CALCULATION
1.	[ ]	BASIC FILING FEE Subtotal (1) \$(Type:)
2.	[ ]	EXTRA CLAIM FEES Subtotal (2) \$
		Total Claims Independent Claims Multiple Dependent Claims
3.	[X]	ADDITIONAL FEES Subtotal (3) \$ 180.00
	,	<pre>[ ] Surcharge - late filing fee or oath [ ] Surcharge - late provisional filing fee or cover     sheet</pre>
		<pre>[ ] Extension for reply within month [ ] Notice of Appeal [ ] Filing a Brief in Support of an appeal [ ] Request for ex parte Reexamination [ ] Petitions to the Commissioner [X] Submission of Information Disclosure Statement [ ] Recording each patent assignment per property [ ] Request for Continued Examination [ ] Other:</pre>
TOTAL	AMOT	UNT OF PAYMENT \$ 180.00
Kathi	) a	August 14, 2003 Doty, Deg. No. 40,593 Date
Kaciii Kato/r	-	. 2001, July 200

\*Enclosure

Express Mail Label No. EV 327052305 US -1 Box

PTO/SB/08A		Comple	te if Known &
INFORMATION DISCLOSURI	E	Application Number	09/843,132
STATEMENT BY APPLICAN	T	Filing Date	April 25, 2001
(use as many sheets as necessa	ary)	Confirmation Number	8349
OTP E VOI		First Named Inventor	John P. McKearn et al.
AUG 1 4 2003 👺		Group Art Unit	1614
P. C. C.		Examiner Name	Unknown
Sheet IR OF 1 of 3	3	Attorney Docket No.	PHA 4301 (3167/12Z)

			U.S	S. PATENT	DOCUMENTS		
		Cite No.1 Number		ment		Date of Publication of Cited Document MM-DD-YYYY	
Examiner Initials*				Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document		
	1.	4,100,2	74		Dutta et al.	07-11-1978	
•	2.	4,140,7	07		Cleare et al.	02-20-1979 12-09-1997	
	3.	5,696,1	31		Baguley et al.		
·	4. 5,733,909		09		Black et al.	03-31-1998 06-16-1998 10-20-1998 02-09-1999	
	5.	<ol> <li>5. 5,767,142</li> <li>6. 5,824,699</li> <li>7. 5,869,524</li> </ol>			LaVoie et al.		
	6.				Kreft et al.		
	7.				Failli		
			FORE	IGN PATE	ENT DOCUMENTS		
		F	oreign Patent Doc	ument			
Examiner Initials*	Cite No. <sup>1</sup>	Office	Number⁴	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Τ°
	8.	EP	0 835 938	A2	Smithkline Beecham Corporation	04-15-1998	
	9.	wo	94/13635	A1	Merck Frosst Canada Inc.	06-23-1994	
	10.	wo	94/20480	A1	Merck Frosst Canada Inc.	09-15-1994	
	11.	wo	94/21612	A1	Otsuka Pharmaceutical Co., Ltd.	09-29-1994	

Examiner	Date	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

PTO/SB/	/08A			Compl	te if Knowing
IN	FORMATION	DISC	LOSURE	Application Number	09/843,132
S	TATEMENT B	Y AP	PLICANT	Filing Date	April 25, 2001
Oluse	as many shee	ets as	necessary)	Confirmation Number	8349
AUG 1	/بيو			First Named Inventor	John P. McKearn et al.
I \	č.			Group Art Unit	1614
SATENT & TE	RADEMA			Examiner Name	Unknown
Sheet	2	of	3	Attorney Docket No.	PHA 4301 (3167/12Z)

12.	wo	94/25431	A1	The Welcome Foundation Limited	11-10-1994
13.	wo	94/26731	A1	Merck Frosst Canada Inc.	11-24-1994
14.	wo	94/27980	A1	G.D. Searle & Co.	12-08-1994
15.	wo	95/11883	A1	G.D. Searle & Co.	05-04-1995
16.	wo	95/15316	A1	G.D. Searle & Co.	06-08-1995
17.	wo	95/30652	A1	G.D. Searle & Co.	11-16-1995
18.	wo	95/30656	A1	G.D. Searle & Co.	11-16-1995
19.	wo	96/03387	A1	G.D. Searle & Co.	02-08-1996
20.	wo	96/03392	A1	G.D. Searle & Co.	02-08-1996
21.	wo	96/06840	A1	Merck Frosst Canada Inc.	03-07-1996
22.	wo	96/21667	A1	Merck Frosst Canada Inc.	07-18-1996
23.	wo	96/33988	A1	Wisconsin Alumni Research Foundation	10-31-1996
24.	wo	96/36612	A1	Rutgers, The State University of New Jersey	11-21-1996
25.	wo	96/36623	A1	Merck Frosst Canada Inc.	11-21-1996
26.	wo	96/37469	A1	Merck Frosst Canada Inc.	11-28-1996
27.	wo	97/15676	A2	Abbott Laboratories	05-01-1997
28.	wo	97/29106	A1	Rutgers, The State University of New Jersey	08-14-1997
29.	wo	97/34608	A1	Mayo Foundation for Medical Education and Research	09-25-1997
	13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28.	13. WO 14. WO 15. WO 16. WO 17. WO 18. WO 20. WO 21. WO 22. WO 23. WO 24. WO 25. WO 27. WO 28. WO	13. WO 94/26731  14. WO 94/27980  15. WO 95/11883  16. WO 95/15316  17. WO 95/30652  18. WO 95/30656  19. WO 96/03387  20. WO 96/03392  21. WO 96/06840  22. WO 96/33988  24. WO 96/36612  25. WO 96/36623  26. WO 97/15676  28. WO 97/29106	13.       WO       94/26731       A1         14.       WO       94/27980       A1         15.       WO       95/11883       A1         16.       WO       95/15316       A1         17.       WO       95/30652       A1         18.       WO       95/30656       A1         19.       WO       96/03387       A1         20.       WO       96/03392       A1         21.       WO       96/06840       A1         22.       WO       96/21667       A1         23.       WO       96/33988       A1         24.       WO       96/36612       A1         25.       WO       96/36623       A1         26.       WO       96/37469       A1         27.       WO       97/15676       A2         28.       WO       97/29106       A1	13.         WO         94/26731         A1         Merck Frosst Canada Inc.           14.         WO         94/27980         A1         G.D. Searle & Co.           15.         WO         95/11883         A1         G.D. Searle & Co.           16.         WO         95/15316         A1         G.D. Searle & Co.           17.         WO         95/30652         A1         G.D. Searle & Co.           18.         WO         95/30656         A1         G.D. Searle & Co.           19.         WO         96/03387         A1         G.D. Searle & Co.           20.         WO         96/03392         A1         G.D. Searle & Co.           21.         WO         96/03892         A1         Merck Frosst Canada Inc.           22.         WO         96/266840         A1         Merck Frosst Canada Inc.           23.         WO         96/33988         A1         Wisconsin Alumni Research Foundation           24.         WO         96/36612         A1         Rutgers, The State University of New Jersey           25.         WO         96/37469         A1         Merck Frosst Canada Inc.           26.         WO         96/37469         A1         Merck Frosst Canada Inc.

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

PTO/SB/0	A80					Complete if Known					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT							Application Number 09		9/843,132 6		
							iling Date	April 25, 2001		0	
( <del>use-</del>	as man	v shee	ets as	necessary)		С	onfirmation Number	83	49	-6	
OLDE	UC/20	,		, , , , , , , , , , , , , , , , , , ,		F	irst Named Inventor	Jo	hn P. McKearn et a	130	
AUG 1 4	ma E						roup Art Unit		14	P	
	200					├─	xaminer Name				
Chook 8 14	WOEN'S					┢			ıknown		
Sheet	3		of 3			Α	Attorney Docket No.		PHA 4301 (3167/12Z)		
<del>- 1</del>	30.	wo	97/3	36863	A1		Merck Frosst Canada Inc.		10-09-1997	Γ	
· <del></del>	31.	wo	98/0	 )3484	A1		Merck Frosst Canada Inc.		01-29-1998		
<del></del>	32.	wo	98/	6227	A1		G.D. Searle & Co.		04-23-1998		
	33.	wo	98/2	22101	A2		G.D. Searle & Co.		05-28-1998	<u> </u>	
	34.	wo	98/2	25896	A1		G.D. Searle & Co. 06-18-1998		06-18-1998		
	35.	wo	98/4	10104	A2		Yale University et al.		09-17-1998		
	36.	wo	99/0	5104	A1		Pfizer Pharmaceuticals Inc.		02-04-1999		
	37.	wo	99/1	0331	A1		Abbott Laboratories		03-04-1999		
	38.	wo	99/1	2930	A1		Glaxo Group Limited		03-18-1999		
	39.	wo	99/1	4194	A1		Merck Frosst Canada Inc.		03-25-1999		
	40.	wo	99/1	4205	A1		Almirall Prodesfarma S.A.		03-25-1999		
	41.	wo	99/4	11241	A1	Rutgers, The State University of New Jersey		f	08-19-1999		
·		ОТ	HER	ART - NON	PATE	EN'	T LITERATURE DOCUM	EN	TS		
Examiner Initials*	Cite No.1	item (book, magazine, journal,				APITAL LETTERS), title of the article (when appropriate), title of the l, serial, symposium, catalog, etc.) date, page(s), volume-issue bublisher, city and/or country where published.			ge(s), volume-issue	Τ <sup>6</sup>	
	42.	International Search Report for Application No. PCT/US02/13219, dated January 13, 2003						ary 13, 2003			
	43.	SUH, N., et al., Novel Triterpenoids Suppress Inducible Nitric Oxide Synthase (iNOS) and Inducyclooxygenase (COX-2) in Mouse Macrophages <sup>1</sup> , Cancer Research, Feb. 15, 1998, pp. 717-Vol. 58						(iNOS) and Inducible 5, 1998, pp. 717-723,			

	 _	
Evaminar	Date	
Examiner	Date	1
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..